[go: up one dir, main page]

FI961418L - Azolderivat och dess farmaceutisk blandning - Google Patents

Azolderivat och dess farmaceutisk blandning Download PDF

Info

Publication number
FI961418L
FI961418L FI961418A FI961418A FI961418L FI 961418 L FI961418 L FI 961418L FI 961418 A FI961418 A FI 961418A FI 961418 A FI961418 A FI 961418A FI 961418 L FI961418 L FI 961418L
Authority
FI
Finland
Prior art keywords
pharmaceutical composition
azole derivative
azole
derivative
pharmaceutical
Prior art date
Application number
FI961418A
Other languages
English (en)
Finnish (fi)
Other versions
FI961418A0 (sv
Inventor
Minoru Okada
Toru Yoden
Eiji Kawaminami
Yoshiaki Shimada
Tsukasa Ishihara
Masafumi Kudou
Original Assignee
Yamanouchi Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharma Co Ltd filed Critical Yamanouchi Pharma Co Ltd
Publication of FI961418A0 publication Critical patent/FI961418A0/sv
Publication of FI961418L publication Critical patent/FI961418L/sv

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI961418A 1993-09-30 1996-03-29 Azolderivat och dess farmaceutisk blandning FI961418L (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP24494493 1993-09-30
PCT/JP1994/001593 WO1995009157A1 (en) 1993-09-30 1994-09-28 Azole derivative and pharmaceutical composition thereof

Publications (2)

Publication Number Publication Date
FI961418A0 FI961418A0 (sv) 1996-03-29
FI961418L true FI961418L (sv) 1996-03-29

Family

ID=17126291

Family Applications (1)

Application Number Title Priority Date Filing Date
FI961418A FI961418L (sv) 1993-09-30 1996-03-29 Azolderivat och dess farmaceutisk blandning

Country Status (12)

Country Link
US (1) US5807880A (sv)
EP (1) EP0721943A4 (sv)
KR (1) KR960704852A (sv)
CN (1) CN1131944A (sv)
AU (1) AU679119B2 (sv)
CA (1) CA2170874A1 (sv)
FI (1) FI961418L (sv)
HU (1) HUT75871A (sv)
NO (1) NO961274L (sv)
NZ (1) NZ273681A (sv)
PL (1) PL313769A1 (sv)
WO (1) WO1995009157A1 (sv)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998006720A1 (fr) 1996-08-09 1998-02-19 Eisai Co., Ltd. Derives de benzopiperidine
AU6229698A (en) * 1997-02-21 1998-09-09 Takeda Chemical Industries Ltd. Fused ring compounds, process for producing the same and use thereof
HUP0004037A3 (en) * 1997-10-02 2002-03-28 Daiichi Seiyaku Co Novel dihydronaphthalene compounds and process for producing the same
US6559157B2 (en) 1997-10-02 2003-05-06 Daiichi Pharmaceutical Co., Ltd. Dihydronaphthalene compounds
CA2328973A1 (en) * 1998-04-23 1999-10-28 Akio Ojida Naphthalene derivatives, their production and use
JP4546589B2 (ja) * 1998-04-23 2010-09-15 武田薬品工業株式会社 ナフタレン誘導体
JP4520012B2 (ja) * 1999-10-22 2010-08-04 武田薬品工業株式会社 1−置換−1−(1h−イミダゾール−4−イル)メタノール類
PE20010781A1 (es) 1999-10-22 2001-08-08 Takeda Chemical Industries Ltd Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion
DE60027034T2 (de) 1999-10-22 2006-11-09 Takeda Pharmaceutical Co. Ltd. 1-substituierte-phenyl-1-(1h-imidazol-4-yl)alkohole, verfahren zu deren herstellung sowie deren verwendung
EP1334106B1 (en) 2000-11-17 2006-05-24 Takeda Pharmaceutical Company Limited Imidazole derivatives, production method thereof and use thereof
CA2429437A1 (en) 2000-11-20 2002-05-23 Takeda Chemical Industries, Ltd. Imidazole derivatives, process for their preparation and their use
WO2002046186A1 (fr) 2000-12-08 2002-06-13 Takeda Chemical Industries, Ltd. Dérivés thiazole substitués porteurs de groupes 3-pyridyl, procédé d'élaboration et leur utilisation
CA2519211A1 (en) * 2003-03-17 2004-09-30 Takeda Pharmaceutical Company Limited Release control compositions
WO2008021250A2 (en) * 2006-08-10 2008-02-21 Fred Hutchinson Cancer Research Center Compositions and methods for modulating apoptosis in cells over-expressing bcl-2 family member proteins
AU2010264698C1 (en) 2009-06-26 2013-05-16 Novartis Ag 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of CYP 17
WO2011041737A2 (en) 2009-10-02 2011-04-07 Fred Hutchinson Cancer Research Center Gain-of-function bcl-2 inhibitors
WO2011041731A2 (en) 2009-10-02 2011-04-07 Fred Hutchinson Cancer Research Center Method of inhibiting bcl-2-related survival proteins
KR101594660B1 (ko) 2010-08-04 2016-02-16 펠피큐어 파마슈티걸즈 아이엔씨 전립선 암종의 치료를 위한 병용 요법
EP2627648A1 (en) 2010-09-16 2013-08-21 Novartis AG 17aHYDROXYLASE/C17,20-LYASE INHIBITORS
CA2820718A1 (en) * 2010-12-13 2012-06-21 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
KR20140025492A (ko) 2011-04-28 2014-03-04 노파르티스 아게 17α-히드록실라제/C17,20-리아제 억제제
JP5990059B2 (ja) * 2012-08-03 2016-09-07 花王株式会社 StAR発現抑制剤
JP6275378B2 (ja) * 2012-12-26 2018-02-07 エヌ・イーケムキャット株式会社 カルバゾール類の製造方法およびこの方法により製造されたカルバゾール類。
CA2902335C (en) 2013-03-14 2021-09-14 Pellficure Pharmaceuticals, Inc. Novel therapy for prostate carcinoma
AU2015314772B2 (en) 2014-09-12 2020-02-27 Pellficure Pharmaceuticals, Inc. Compositions and methods for treatment of prostate carcinoma
WO2018080933A1 (en) 2016-10-24 2018-05-03 Pellficure Pharmaceuticals Inc. Pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1, 4-dione
CN109748884B (zh) * 2019-02-19 2022-06-24 成都恒昊创新科技有限公司 一种铁死亡抑制剂及其制备方法与应用
EP3786156B1 (en) * 2018-04-27 2024-06-05 Chengdu Henghao Investment Co. Limited 10h-phenothiazine ferroptosis inhibitor and preparation method therefor and application thereof
WO2021098715A1 (zh) * 2019-11-21 2021-05-27 成都恒昊投资有限公司 一种吩噻嗪类铁死亡抑制剂及其制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ221729A (en) * 1986-09-15 1989-07-27 Janssen Pharmaceutica Nv Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions
DE3942227A1 (de) * 1989-12-21 1991-06-27 Bayer Ag Triarylmethan-farbbildner
GB9310635D0 (en) * 1993-05-21 1993-07-07 Glaxo Group Ltd Chemical compounds
WO1995004723A1 (fr) * 1993-08-04 1995-02-16 Yamanouchi Pharmaceutical Co., Ltd. Derive d'imidazolylalkylamine et composition pharmaceutique contenant ledit derive

Also Published As

Publication number Publication date
KR960704852A (ko) 1996-10-09
HUT75871A (en) 1997-05-28
AU679119B2 (en) 1997-06-19
CN1131944A (zh) 1996-09-25
CA2170874A1 (en) 1995-04-06
FI961418A0 (sv) 1996-03-29
HU9600813D0 (en) 1996-05-28
NO961274D0 (no) 1996-03-29
NZ273681A (en) 1996-09-25
WO1995009157A1 (en) 1995-04-06
EP0721943A4 (en) 1996-09-04
PL313769A1 (en) 1996-07-22
US5807880A (en) 1998-09-15
EP0721943A1 (en) 1996-07-17
NO961274L (no) 1996-03-29
AU7707194A (en) 1995-04-18

Similar Documents

Publication Publication Date Title
FI961418L (sv) Azolderivat och dess farmaceutisk blandning
BR1100824A (pt) Composto e composição farmacêutica
FI961599A (sv) 1N-alkyl-N-arylpyrimidinaminer och derivat därav
BR1100329A (pt) Composto e formulação farmacêutica
FI944832A0 (sv) Farmaceutisk sammansättning
FI941747L (sv) Kompositioner och deras användnigar
FI941137L (sv) 2-debensoyl-2-acyltaxolderivat och förfaranden för framställning av dessa
FI943345L (sv) Organalumoxanprodukter och deras användning
FI945476L (sv) Sammansättningar med fördröjd frigörning och förfarande för framställning av farmaceutiska sammansättningar
BR9500784A (pt) Composto e formulação farmacêutica
BR9504060A (pt) Composto e formulação farmacêutica
FI953479A0 (sv) 1-arylpyrimidinderivat och farmaceutisk användning av dessa
FI940640L (sv) Organoaluminoxyprodukter samt användning
FI945434L (sv) 4-merkaptoacetylamino-/2/benzazepinone(3) derivat och användning av dessa som enkefalinasinhibitorer
PT703954E (pt) Composicoes de derivados de polifenois e sua preparacao
BR9200058A (pt) Composto e composicao farmaceutica
FI960867A (sv) Bensazepinderivat, dess farmaceutisk blandning och mellanprodukt
ITMI932540A0 (it) Composizione farmaceutica
BR9509688A (pt) Composto e composição farmacêutica
FI960487L (sv) Bensopyraner och dessa innehållande farmaceutiska kompositioner
FI943705L (sv) Farmaceutiska kompositioner
FI971462L (sv) Bensioxazolderivat och bekämpningsmedelssammansättningar innehållande desamma
LV10579A (lv) Farmaceitiska kompozicija
FI934387A0 (fi) 3-substituerade 2-oxi-indol-1-karboxiamid omfattande farmaceutiska kompositioner
FI956235L (sv) 17-halogen-4-aza-androstenderivat och förfarande för framställning av dem